Compounds > efavirenz--emtricitabine--tenofovir-disoproxil-fumarate-drug-combination

efavirenz--emtricitabine--tenofovir-disoproxil-fumarate-drug-combination and Renal-Insufficiency

efavirenz--emtricitabine--tenofovir-disoproxil-fumarate-drug-combination has been researched along with Renal-Insufficiency* in 1 studies

Trials

1 trial(s) available for efavirenz--emtricitabine--tenofovir-disoproxil-fumarate-drug-combination and Renal-Insufficiency

Article	Year
Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3 We performed a randomized controlled trial in 30 HIV-infected participants to either continue tenofovir/emtricitabine/efavirenz (Continuation Group) or switch to tenofovir/emtricitabine/raltegravir (Switch Group) for 24 weeks. There were no significant differences in the changes in flow-mediated dilation, 25(OH) vitamin D, or parathyroid hormone levels. Total cholesterol, high sensitivity C-reactive protein, serum alkaline phosphatase, sCD14 levels, and renal function significantly declined in the Switch Group compared with the Continuation Group; however, sCD163 levels significantly increased in the Switch Group. These findings suggest that raltegravir is not inherently more beneficial to endothelial function compared with efavirenz but may impact renal function and monocyte activation. Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Biomarkers; Bone and Bones; C-Reactive Protein; Cholesterol; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Endothelium, Vascular; Female; HIV Infections; Humans; Indiana; Inflammation; Male; Organophosphonates; Oxazines; Pyrrolidinones; Raltegravir Potassium; Renal Insufficiency; Treatment Outcome; Viral Load	2013

Article

Year

Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.

Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3

We performed a randomized controlled trial in 30 HIV-infected participants to either continue tenofovir/emtricitabine/efavirenz (Continuation Group) or switch to tenofovir/emtricitabine/raltegravir (Switch Group) for 24 weeks. There were no significant differences in the changes in flow-mediated dilation, 25(OH) vitamin D, or parathyroid hormone levels. Total cholesterol, high sensitivity C-reactive protein, serum alkaline phosphatase, sCD14 levels, and renal function significantly declined in the Switch Group compared with the Continuation Group; however, sCD163 levels significantly increased in the Switch Group. These findings suggest that raltegravir is not inherently more beneficial to endothelial function compared with efavirenz but may impact renal function and monocyte activation.

Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Biomarkers; Bone and Bones; C-Reactive Protein; Cholesterol; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Endothelium, Vascular; Female; HIV Infections; Humans; Indiana; Inflammation; Male; Organophosphonates; Oxazines; Pyrrolidinones; Raltegravir Potassium; Renal Insufficiency; Treatment Outcome; Viral Load

2013